Antigenic transformation in plasma cell dyscrasia

被引:1
作者
Cruse, Julius A. [1 ]
Lewis, Robert E. [1 ]
Webb, Rachel N. [1 ]
Sanders, Catherine A. [1 ]
Tillman, Benjamin F. [1 ]
Beason, Kevin [1 ]
Lam, John [1 ]
Koehler, Jonathan [1 ]
机构
[1] Univ Mississippi, Med Ctr, Dept Pathol, Jackson, MS 39216 USA
关键词
plasma cell dyscrasia; CD138; CD38; CD56; CD19; mean fluorescence intensity (MFI); antigenic transformation;
D O I
10.1016/j.yexmp.2006.06.005
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
The WHO immunophenotype for plasma cell myeloma is deletion of CD19 and CD20, usual expression of CD38, CD138, and CD56, and occasional expression of CD10. Of the 39 cases of plasma cell dyscrasia in our study, the mean fluorescence intensities (MFI) of CD38, CD138, CD56, and CD19 were quantified in 30 cases. CD19 was absent in 38 of the cases (97.4%), whereas CD138 and CD38 were expressed in all 39 cases (100%). Most cases expressed CD38 and CD138 brightly with MF1 values greater than 501, whereas all other marker expression was moderate with MFI greater than 301. Whereas CD38/CD56 dual expression was observed in 25 cases (64.1%), 14 failed to express CD56 (35.9%). CD56 expression was bright in 16 cases (53.3%), moderate in 2 cases (6.7%), and negative in the remaining 12 cases (40%) with MFI values of 200 or less. CD117 expression was positive in 9 of 24 cases (37.5%). In 32 of 39 cases, 27 were negative for CD20 (84.4%) and 28 were negative for CD10 (87.5%). Our results point to the value of quantitative fluorescence intensity in the flow cytometric evaluation of CD molecular expression or deletion in the diagnosis of hernatopathologic disorders, such as plasma cell dyscrasia. (c) 2006 Elsevier Inc. All rights reserved.
引用
收藏
页码:157 / 161
页数:5
相关论文
共 19 条
[1]   High-sensitive immunophenotyping and DNA ploidy studies for the investigation of minimal residual disease in multiple myeloma [J].
Almeida, J ;
Orfao, A ;
Ocqueteau, M ;
Mateo, G ;
Corral, M ;
Caballero, MD ;
Blade, J ;
Moro, MJ ;
Hernandez, J ;
San Miguel, JF .
BRITISH JOURNAL OF HAEMATOLOGY, 1999, 107 (01) :121-131
[2]  
Bain BJ, 2001, BONE MARROW PATHOLOG
[3]  
Cruse J. M., 2004, IMMUNOLOGY GUIDEBOOK
[4]  
GROGAN TM, 1987, BLOOD, V70, P932
[5]  
HARADA H, 1993, BLOOD, V81, P2658
[6]  
Jaffe ES., 2001, WHO CLASSIFICATION T
[7]   IDENTITY OF LEU-19 (CD56) LEUKOCYTE DIFFERENTIATION ANTIGEN AND NEURAL CELL-ADHESION MOLECULE [J].
LANIER, LL ;
TESTI, R ;
BINDL, J ;
PHILLIPS, JH .
JOURNAL OF EXPERIMENTAL MEDICINE, 1989, 169 (06) :2233-2238
[8]   Surface and cytoplasmic immunoglobulin expression in B-cell chronic lymphocytic leukemia (CLL) [J].
Lewis, RE ;
Cruse, JM ;
Pierce, S ;
Lam, J ;
Tadros, Y .
EXPERIMENTAL AND MOLECULAR PATHOLOGY, 2005, 79 (02) :146-150
[9]   Flow cytometric immunophenotypic analysis of 306 cases of multiple myeloma [J].
Lin, P ;
Owens, R ;
Tricot, G ;
Wilson, CS .
AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2004, 121 (04) :482-488
[10]   Rare KIT (CD117) expression in multiple myeloma abrogates the usefulness of imatinib mesylate treatment [J].
Lugli, A ;
Went, P ;
Khanlari, B ;
Nikolova, Z ;
Dirnhofer, S .
VIRCHOWS ARCHIV, 2004, 444 (03) :264-268